FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014238213> ?p ?o ?g. }

• W2014238213 abstract "Abstract Background Over-expression of HER2 in a subset of breast cancers ( HER2 +) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2 + patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients. Methods A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH) was screened by immunohistochemistry staining using a large number of novel and commercially available antibodies to identify those with a univariate association with clinical outcome in HER2 + patients. Staining with antibody directed at TRMT2A was found to be strongly associated with outcome in HER2 + patients. This association with outcome was tested in two independent validation cohorts; an existing staining dataset derived from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI). Results TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2 + patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p < 0.0004). This association with outcome was confirmed using 75 HER2 + patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p < 0.02) and 64 patients from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p < 0.02). In bivariable analysis the association with outcome was independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in the CCIH and RPCI cohorts. Conclusions Studies from three independent single institution cohorts support TRMT2A protein expression as a biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A expression should be further studied in the clinical trial setting to explore its predictive power for response to adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy." @default.
• W2014238213 created "2016-06-24" @default.
• W2014238213 creator A5005296830 @default.
• W2014238213 creator A5012416074 @default.
• W2014238213 creator A5021029414 @default.
• W2014238213 creator A5023510235 @default.
• W2014238213 creator A5025465348 @default.
• W2014238213 creator A5028987280 @default.
• W2014238213 creator A5030476275 @default.
• W2014238213 creator A5033135467 @default.
• W2014238213 creator A5034318098 @default.
• W2014238213 creator A5047604705 @default.
• W2014238213 creator A5056296851 @default.
• W2014238213 creator A5059707915 @default.
• W2014238213 creator A5064936288 @default.
• W2014238213 creator A5074787333 @default.
• W2014238213 creator A5075171048 @default.
• W2014238213 creator A5089797416 @default.
• W2014238213 date "2010-03-22" @default.
• W2014238213 modified "2023-09-27" @default.
• W2014238213 title "The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence" @default.
• W2014238213 cites W1837870834 @default.
• W2014238213 cites W2022121606 @default.
• W2014238213 cites W2032141702 @default.
• W2014238213 cites W2045324973 @default.
• W2014238213 cites W2081923162 @default.
• W2014238213 cites W2095156669 @default.
• W2014238213 cites W2097255042 @default.
• W2014238213 cites W2105712639 @default.
• W2014238213 cites W2128840351 @default.
• W2014238213 cites W2130588419 @default.
• W2014238213 cites W2131994307 @default.
• W2014238213 cites W2140074016 @default.
• W2014238213 cites W2141393790 @default.
• W2014238213 cites W2143336748 @default.
• W2014238213 cites W2146384083 @default.
• W2014238213 cites W2148867790 @default.
• W2014238213 cites W2154901002 @default.
• W2014238213 cites W2157840751 @default.
• W2014238213 cites W2159459001 @default.
• W2014238213 cites W2160329331 @default.
• W2014238213 doi "https://doi.org/10.1186/1471-2407-10-108" @default.
• W2014238213 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2859753" @default.
• W2014238213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20307320" @default.
• W2014238213 hasPublicationYear "2010" @default.
• W2014238213 type Work @default.
• W2014238213 sameAs 2014238213 @default.
• W2014238213 citedByCount "29" @default.
• W2014238213 countsByYear W20142382132012 @default.
• W2014238213 countsByYear W20142382132014 @default.
• W2014238213 countsByYear W20142382132016 @default.
• W2014238213 countsByYear W20142382132017 @default.
• W2014238213 countsByYear W20142382132018 @default.
• W2014238213 countsByYear W20142382132019 @default.
• W2014238213 countsByYear W20142382132020 @default.
• W2014238213 countsByYear W20142382132021 @default.
• W2014238213 countsByYear W20142382132022 @default.
• W2014238213 countsByYear W20142382132023 @default.
• W2014238213 crossrefType "journal-article" @default.
• W2014238213 hasAuthorship W2014238213A5005296830 @default.
• W2014238213 hasAuthorship W2014238213A5012416074 @default.
• W2014238213 hasAuthorship W2014238213A5021029414 @default.
• W2014238213 hasAuthorship W2014238213A5023510235 @default.
• W2014238213 hasAuthorship W2014238213A5025465348 @default.
• W2014238213 hasAuthorship W2014238213A5028987280 @default.
• W2014238213 hasAuthorship W2014238213A5030476275 @default.
• W2014238213 hasAuthorship W2014238213A5033135467 @default.
• W2014238213 hasAuthorship W2014238213A5034318098 @default.
• W2014238213 hasAuthorship W2014238213A5047604705 @default.
• W2014238213 hasAuthorship W2014238213A5056296851 @default.
• W2014238213 hasAuthorship W2014238213A5059707915 @default.
• W2014238213 hasAuthorship W2014238213A5064936288 @default.
• W2014238213 hasAuthorship W2014238213A5074787333 @default.
• W2014238213 hasAuthorship W2014238213A5075171048 @default.
• W2014238213 hasAuthorship W2014238213A5089797416 @default.
• W2014238213 hasBestOaLocation W20142382131 @default.
• W2014238213 hasConcept C121608353 @default.
• W2014238213 hasConcept C126322002 @default.
• W2014238213 hasConcept C142724271 @default.
• W2014238213 hasConcept C143998085 @default.
• W2014238213 hasConcept C167135981 @default.
• W2014238213 hasConcept C204232928 @default.
• W2014238213 hasConcept C2779786085 @default.
• W2014238213 hasConcept C2780140570 @default.
• W2014238213 hasConcept C530470458 @default.
• W2014238213 hasConcept C71924100 @default.
• W2014238213 hasConcept C72563966 @default.
• W2014238213 hasConceptScore W2014238213C121608353 @default.
• W2014238213 hasConceptScore W2014238213C126322002 @default.
• W2014238213 hasConceptScore W2014238213C142724271 @default.
• W2014238213 hasConceptScore W2014238213C143998085 @default.
• W2014238213 hasConceptScore W2014238213C167135981 @default.
• W2014238213 hasConceptScore W2014238213C204232928 @default.
• W2014238213 hasConceptScore W2014238213C2779786085 @default.
• W2014238213 hasConceptScore W2014238213C2780140570 @default.
• W2014238213 hasConceptScore W2014238213C530470458 @default.
• W2014238213 hasConceptScore W2014238213C71924100 @default.
• W2014238213 hasConceptScore W2014238213C72563966 @default.
• W2014238213 hasIssue "1" @default.
• W2014238213 hasLocation W20142382131 @default.

• next